[1] LI Shanahan SUN Qian YANG Shaoning YU Xiaoyong,.Relationship Between Intestinal Flora Imbalance and Chronic Kidney Disease [J]. Modern Traditional Chinese Medicine, 2022, 1(03): 16-21. [doi: 10.13424/j.cnki.mtcm.2022.03.003]
Relationship Between Intestinal Flora Imbalance and Chronic Kidney Disease
- Article number:
- 1672-0571(2022)03-0016-06
- Keywords:
- Key words：Chronic kidney disease; Imbalance of intestinal flora; Probiotics; Fecal bacteria transplantation; Traditional Chinese Medicine
- ZTFLH:
- R265.5
- Code:
- A
- Abstract:
- Abstract：In recent years，chronic kidney disease (CKD) has increasingly become a global public health problem，and the disease burden is gradually increasing in China and even all over the world.Many modern studies have confirmed that there is a correlation between intestinal flora imbalance and many diseases.The relationship between intestinal flora imbalance and chronic kidney disease has also become a research hotspot.Due to the accumulation of uremic toxin in the body，CKD patients change the structure and composition of intestinal flora，destroy the barrier function of intestinal epithelium，activate the immune regulation function of intestinal tract，make harmful substances such as bacteria and toxins enter the blood，induce systemic lesions，and finally damage the kidney and form a vicious circle.Probiotics and other probiotics，fecal bacteria transplantation，traditional Chinese medicine and other intervention methods can stabilize the intestinal flora，repair the barrier function of intestinal epithelial mucosa，reduce the accumulation of enterogenous urotoxin，delay the progress of CKD and play the role of renal protection.Therefore，regulating intestinal flora disorder may be a new target for the prevention and treatment of CKD.
References:
［1］GBD Chronic Kidney Disease Collaboration.Global,regional,and national burden of chronic kidney disease,1990-2017:a systematic analysis for the global burden of disease study 2017［J].Lancet，2020，395(10225):709-733.
［2]Lv JC,Zhang LX.Prevalence and disease burden of chronic kidney disease［J].Advances in Experimental Medicine and Biology,2019,1165:3-15.
［3]Sabatino A,Regolisti G,Brusasco I,et al.Alterations of intestinal barrier and microbiota in chronic kidney disease［J].Nephrology Dialysis Transplantation,2014,30(6):924-933.
［4]Glenwright AJ,Pothula KR,Bhamidimarri SP,et al.Structural basis for nutrient acquisition by dominant members of the human gut microbiota［J].Nature,2017,541(7637):407-411.
［5]Tropini C,Earle KA,Huang KC,et al.The gut microbiome:connecting spatial organization to function［J].Cell Host & Microbe,2017,21(4):433-442.
［6]魏丽雪,杜玄.肠道菌群与肾脏病研究新进展［J].中国中西医结合肾病杂志,2020,21(5):453-455.
［7]Anders HJ,Andersen K,Stecher B.The intestinal microbiota,a leaky gut,and abnormal immunity in kidney disease［J].Kidney International,2013,83(6):1010-1016.
［8]Simrén M,Barbara G,Flint HJ,et al.Intestinal microbiota in functional bowel disorders:a Rome foundation report［J].Gut,2013,62(1):159-176.
［9]Fujisaka S,Avila-Pacheco J,Soto M,et al.Diet,genetics,and the gut microbiome drive dynamic changes in plasma metabolites［J].Cell Reports,2018,22(11):3072-3086.
［10]Furusawa Y,Obata Y,Fukuda S,et al.Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells［J].Nature,2013,504(7480):446-450.
［11]Meijers BKI,Evenepoel P.The gut-kidney axis:indoxyl sulfate,p-cresyl sulfate and CKD progression［J].Nephrology,Dialysis,Transplantation,2011,26(3):759-761.
［12]Pahl MV,Vaziri ND.The chronic kidney disease - colonic axis［J].Seminars in Dialysis,2015,28(5):459-463.
［13]刁宗礼,刘文虎,阴赪宏.肠道菌群与慢性肾脏病的相关性［J].中国医刊,2019,54(6):595-597.
［14]包文晗,王悦.慢性肾脏病患者肠道菌群的变化及影响研究［J].中国全科医学,2018,21(24):2927-2931.
［15]韩文贝,刘莹露,万毅刚,等.慢性肾脏病肠道菌群失调的病理机制、治疗策略及中药的干预作用［J].中国中药杂志,2017,42(13):2425-2432.
［16]Koppe L,Fouque D,Soulage CO.The role of gut microbiota and diet on uremic retention solutes production in the context of chronic kidney disease［J].Toxins,2018,10(4):155.
［17]Kim SM,Song IH.The clinical impact of gut microbiota in chronic kidney disease［J].The Korean Journal of Internal Medicine,2020,35(6):1305-1316.
［18]Vanholder R,Baurmeister U,Brunet P,et al.A bench to bedside view of uremic toxins［J].Journal of the American Society of Nephrology:JASN,2008,19(5):863-870.
［19]Graboski AL,Redinbo MR.Gut-derived protein-bound uremic toxins［J].Toxins,2020,12(9):590.
［20]Ueno H,Koyama H,Fukumoto S,et al.Advanced glycation end products,carotid atherosclerosis,and circulating endothelial progenitor cells in patients with end-stage renal disease［J].Metabolism:Clinical and Experimental,2011,60(4):453-459.
［21]Lees HJ,Swann JR,Wilson ID,et al.Hippurate:the natural history of a mammalian-microbial cometabolite［J].Journal of Proteome Research,2013,12(4):1527-1546.
［22]McIntyre CW,Harrison LE,Eldehni MT,et al.Circulating endotoxemia:a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease［J].Clinical Journal of the American Society of Nephrology:CJASN,2011,6(1):133-141.
［23]Ramezani A,Raj DS.The gut microbiome,kidneydisease,and targeted interventions［J].Journal of the American Society of Nephrology,2014,25(4):657-670.
［24]Rice JB,Stoll LL,Li WG,et al.Low-level endotoxin induces potent inflammatory activation of human blood vessels:inhibition by statins［J].Arteriosclerosis,Thrombosis,and Vascular Biology,2003,23(9):1576-1582.
［25]王仡豪,郁胜强.慢性肾脏病与肠道微生态的相互影响［J].临床肾脏病杂志,2019,19(9):700-705.
［26]Ivanov II,Atarashi K,Manel N,et al.Induction of intestinal Th17 cells by segmented filamentous bacteria［J].Cell,2009,139(3):485-498.
［27]Chen YY,Chen DQ,Chen L,et al.Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease［J].Journal of Translational Medicine,2019,17(1):5.
［28]Yang T,Richards EM,Pepine CJ,et al.The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease［J].Nature Reviews Nephrology,2018,14(7):442-456.
［29]Maynard CL,Elson CO,Hatton RD,et al.Reciprocal interactions of the intestinal microbiota and immune system［J].Nature,2012,489(7415):231-241.
［30]Johnson-Henry KC,Hagen KE,Gordonpour M,et al.Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells［J].Cellular Microbiology,2007,9(2):356-367.
［31]Vaziri ND,Liu SM,Lau WL,et al.High amylose resistant starch diet ameliorates oxidative stress,inflammation,and progression of chronic kidney disease［J].PLoS One,2014,9(12):e114881.
［32]Rossi M,Johnson DW,Campbell KL.The kidney-gut axis:implications for nutrition care［J].Journal of Renal Nutrition,2015,25(5):399-403.
［33]周韩菁,朱菡,姚颖.益生菌干预:慢性肾脏病治疗的新策略［J].中国医刊,2018,53(9):953-957，948.
［34]张镭,聂静.肠道菌群与慢性肾脏病［J].临床肾脏病杂志,2016,16(11):697-700.
［35]张小娟,蒋珍秀,董娜.基于肠道微生态及“肠-肾轴”理论探讨慢性肾脏病从脾论治机理［J].中国中医药信息杂志,2020,27(6):14-17.
［36]孔畅，陈东峰，赵泉霖.从肠道菌群探讨肥胖从脾论治的机理［J].中国中医基础医学杂志，2017,23(9):1214-1216.
［37]杨康,纪越,赵庆云,等.慢性肾脏病与肠道微生态的关系、治疗策略及中医药干预研究［J].中医药学报,2019,47(1):1-6.
［38]裴明,杨洪涛.从肠道微生态看中医肾病学的发展机遇［J].中华中医药杂志,2019,34(6):2336-2341.
［39]李玉丽,肖嫩群,谭周进.代谢性疾病的肠道菌群相关研究进展［J].世界华人消化杂志,2020,28(23):1192-1199.
［40]邹秋萍,李婷,李艳平.中药及活性成分通过影响肠道菌群干预结直肠癌的研究进展［J].国际药学研究杂志,2020,47(12):1027-1032.
［41]姚东升,叶朝阳.基于“肠-肾轴”中医药治疗慢性肾脏病的研究进展［J].内蒙古中医药,2020,39(12):159-160.
［42]Xu J,Chen HB,Li SL.Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota［J].Medicinal Research Reviews,2017,37(5):1140-1185.
［43]樊均明,马欣,文集.肠道菌群的微生态改变与慢性肾脏疾病［J].中国中西医结合肾病杂志,2013,14(12):1035-1037.
Memo
基金项目：陕西省科技厅社发攻关一般项目（2017SF-298）；西安市科技计划项目（2019114613YX001SF044）